Discover
TLPH
Talphera, Inc.
1.05
1 x 1.02
1 x 1.06
bid
ask
+
0.02
1.94%
1 @ 04:00 PM
1.07 +0.02 (1.76%)
| Ytd | -7.89% | |
| 1y | 133.33% |
1.00
day range
1.06
0.38
52 week range
1.57
| Open | 1.04 | Prev Close | 1.03 | Low | 1.00 | High | 1.06 | Mkt Cap | 54.49M |
| Vol | 365.48K | Avg Vol | 180.36K | EPS | -0.28 | P/E | N/A | Forward P/E | -0.63 |
| Beta | 0.30 | Short Ratio | 0.85 | Inst. Own | 29.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.87 | 200-d Avg | 0.99 | 1yr Est | 4.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.2 | -0.13 | 0.07 | 35.00% |
| 2024-08-14 | 2024-06 | -0.22 | -0.15 | 0.07 | 31.82% |
| 2024-05-14 | 2024-03 | -0.28 | -0.16 | 0.12 | 42.86% |
| 2024-03-06 | 2023-12 | -0.24 | -0.25 | -0.01 | -4.17% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-06 | Maxim Group | Upgrade | Buy | |
| 2024-03-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-01-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-12-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-23 | ADAMS ADRIAN | Director | 13.34K | Stock Award(Grant) |
| 2024-12-04 | ANGOTTI VINCENT J | Chief Executive Officer | 208.07K | Purchase |
| 2024-12-01 | ASADORIAN RAFFI | Chief Financial Officer | 37.58K | Sale |
| 2024-06-23 | BOZILENKO MARINA | Director | 4.78K | Stock Award(Grant) |
| 2024-06-23 | BROADFOOT JILL MARIE | Director | 4.28K | Stock Award(Grant) |
| 2024-02-13 | DASU BADRI N | Officer | 31.82K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Nantahala Capital Management, LLC | 1.99M | 1.22M | 11.70% |
| 2024-09-29 | Rosalind Advisors, Inc. | 758.97K | 465.25K | 4.46% |
| 2024-09-29 | Rock Springs Capital Management, LP | 316.46K | 193.99K | 1.86% |
| 2024-09-29 | MAI Capital Management | 282.34K | 173.08K | 1.66% |
| 2024-09-29 | Vanguard Group Inc | 240.97K | 147.71K | 1.42% |
| 2024-09-29 | Geode Capital Management, LLC | 155.50K | 95.32K | 0.91% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 159.61K | 97.84K | 0.94% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 97.09K | 59.52K | 0.57% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 81.36K | 49.87K | 0.48% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 22.89K | 14.03K | 0.13% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 16.37K | 10.03K | 0.10% |
| 2024-10-30 | Fidelity Total Market Index Fund | 15.76K | 9.66K | 0.09% |